These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35269726)

  • 1. Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders.
    Ko KR; Lee H; Han SH; Ahn W; Kim DK; Kim IS; Jung BS; Lee S
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
    Nizam E; Erin N
    Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P and the Neurokinin-1 Receptor: The New CRF.
    Schank JR; Heilig M
    Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurokinin 1 Receptor Antagonists for Pruritus.
    Alam M; Buddenkotte J; Ahmad F; Steinhoff M
    Drugs; 2021 Apr; 81(6):621-634. PubMed ID: 33675531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neurokinin-1 receptor in addictive processes.
    Schank JR
    J Pharmacol Exp Ther; 2014 Oct; 351(1):2-8. PubMed ID: 25038175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders.
    Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI
    Life Sci; 2022 May; 296():120448. PubMed ID: 35247438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substance P enhances the local activation of NK
    Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
    BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
    Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
    Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis.
    Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J
    FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance P and the neurokinin-1 receptor expression in dog ileum with and without inflammation.
    Polidoro G; Giancola F; Fracassi F; Pietra M; Bettini G; Asti M; Chiocchetti R
    Res Vet Sci; 2017 Oct; 114():297-307. PubMed ID: 28628846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation.
    Sosulina L; Strippel C; Romo-Parra H; Walter AL; Kanyshkova T; Sartori SB; Lange MD; Singewald N; Pape HC
    J Neurophysiol; 2015 Oct; 114(4):2500-8. PubMed ID: 26334021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.
    Jensen DD; Lieu T; Halls ML; Veldhuis NA; Imlach WL; Mai QN; Poole DP; Quach T; Aurelio L; Conner J; Herenbrink CK; Barlow N; Simpson JS; Scanlon MJ; Graham B; McCluskey A; Robinson PJ; Escriou V; Nassini R; Materazzi S; Geppetti P; Hicks GA; Christie MJ; Porter CJH; Canals M; Bunnett NW
    Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of neurokinin-1 receptors up-regulates substance P and neurokinin-1 receptor expression in murine pancreatic acinar cells.
    Koh YH; Moochhala S; Bhatia M
    J Cell Mol Med; 2012 Jul; 16(7):1582-92. PubMed ID: 22040127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
    Herpfer I; Lieb K
    CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
    Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
    Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of neurogenic substance P in overexpression of alveolar macrophages' neurokinin 1 receptor in mice exposed to cigarette smoke.
    Xu J; Xu F
    Exp Lung Res; 2010 May; 36(4):243-54. PubMed ID: 20426532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
    Ständer S; Yosipovitch G
    Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of CP96,345 on the expression of tachykinins and neurokinin receptors in acute pancreatitis.
    Lau HY; Bhatia M
    J Pathol; 2006 Feb; 208(3):364-71. PubMed ID: 16369913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.